Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:WNT2-ST7

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: WNT2-ST7
	FusionPDB ID: 99361
	FusionGDB2.0 ID: 99361
		Hgene	Tgene
	Gene symbol	WNT2	ST7
	Gene ID	7472	93655
	Gene name	Wnt family member 2	ST7 overlapping transcript 3
	Synonyms	INT1L1\|IRP	NCRNA00026\|ST7\|ST7OT3
	Cytomap	7q31.2	7q31.2
	Type of gene	protein-coding	ncRNA
	Description	protein Wnt-2Int-1-related proteinepididymis secretory sperm binding proteinint-1-like protein 1secreted growth factorwingless-type MMTV integration site family member 2	ST7 overlapping transcript 3 (non-coding RNA)ST7 overlapping transcript 3 (non-protein coding)suppression of tumorigenicity 7
	Modification date	20200313	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000265441,	ENST00000393443, ENST00000393444, ENST00000393447, ENST00000465133, ENST00000487459, ENST00000265437, ENST00000323984, ENST00000393446, ENST00000393449, ENST00000393451, ENST00000422922, ENST00000432298,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	2 X 2 X 1=4	13 X 10 X 8=1040
	# samples	1	14
	** MAII score	log2(1/4*10)=1.32192809488736	log2(14/1040*10)=-2.89308479608349 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: WNT2 [Title/Abstract] AND ST7 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: WNT2 [Title/Abstract] AND ST7 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	WNT2(116937666)-ST7(116739816), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	WNT2	GO:0007267	cell-cell signaling	10557084
Hgene	WNT2	GO:0008284	positive regulation of cell proliferation	10347172
Hgene	WNT2	GO:0033278	cell proliferation in midbrain	20018874
Hgene	WNT2	GO:0045944	positive regulation of transcription by RNA polymerase II	20018874
Hgene	WNT2	GO:0051091	positive regulation of DNA-binding transcription factor activity	10557084
Hgene	WNT2	GO:0060070	canonical Wnt signaling pathway	10347172\|10557084\|20018874
Hgene	WNT2	GO:1904948	midbrain dopaminergic neuron differentiation	20018874
Hgene	WNT2	GO:1904954	canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation	20018874

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:116937666/chr7:116739816)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across WNT2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ST7 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000265441	WNT2	chr7	116937666	-	ENST00000393446	ST7	chr7	116739816	+	2813	1153	300	2573	757
ENST00000265441	WNT2	chr7	116937666	-	ENST00000265437	ST7	chr7	116739816	+	3687	1153	300	2759	819
ENST00000265441	WNT2	chr7	116937666	-	ENST00000393451	ST7	chr7	116739816	+	2913	1153	300	2666	788
ENST00000265441	WNT2	chr7	116937666	-	ENST00000393449	ST7	chr7	116739816	+	2967	1153	300	2720	806
ENST00000265441	WNT2	chr7	116937666	-	ENST00000323984	ST7	chr7	116739816	+	2982	1153	300	2735	811
ENST00000265441	WNT2	chr7	116937666	-	ENST00000432298	ST7	chr7	116739816	+	2982	1153	300	2735	811
ENST00000265441	WNT2	chr7	116937666	-	ENST00000422922	ST7	chr7	116739816	+	2913	1153	300	2666	788

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000265441	ENST00000393446	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.005962112	0.99403787
ENST00000265441	ENST00000265437	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.003244224	0.9967558
ENST00000265441	ENST00000393451	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.004689767	0.99531025
ENST00000265441	ENST00000393449	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.004186044	0.9958139
ENST00000265441	ENST00000323984	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.003960437	0.9960395
ENST00000265441	ENST00000432298	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.003960437	0.9960395
ENST00000265441	ENST00000422922	WNT2	chr7	116937666	-	ST7	chr7	116739816	+	0.004689767	0.99531025

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for WNT2-ST7

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
WNT2	chr7	116937666	ST7	chr7	116739816	1153	284	ENSPDYCIRDREAVSMFLNTLTPKFY

Top

Potential FusionNeoAntigen Information of WNT2-ST7 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

WNT2-ST7_116937666_116739816.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B47:01	REAVSMFL	0.9921	0.6654	10	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:13	REAVSMFL	0.9673	0.9627	10	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:24	IRDREAVSM	0.9969	0.5729	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:01	DREAVSMFL	0.996	0.9002	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:01	DREAVSMFL	0.996	0.8101	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:02	DREAVSMFL	0.996	0.8101	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B27:07	IRDREAVSM	0.9944	0.5587	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:02	IRDREAVSM	0.9938	0.8697	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:01	IRDREAVSM	0.9938	0.8697	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:01	IRDREAVSM	0.9936	0.9101	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:02	DREAVSMFL	0.993	0.946	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:01	DREAVSMFL	0.9927	0.9419	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:02	IRDREAVSM	0.9872	0.9671	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:01	IRDREAVSM	0.9851	0.9656	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:37	DREAVSMFL	0.95	0.5767	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:10	IRDREAVSM	0.8889	0.5113	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:18	IRDREAVSM	0.8701	0.7404	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:37	IRDREAVSM	0.8672	0.6476	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:10	DREAVSMFL	0.866	0.6415	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B47:01	RDREAVSMF	0.4357	0.6839	8	17
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B27:07	RDREAVSMFL	0.9713	0.5757	8	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:08	REAVSMFL	0.982	0.8211	10	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:09	DREAVSMFL	0.9959	0.7607	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:12	DREAVSMFL	0.9946	0.9056	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:09	IRDREAVSM	0.9944	0.8286	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:05	IRDREAVSM	0.9937	0.9577	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:95	IRDREAVSM	0.9933	0.7409	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:12	IRDREAVSM	0.9928	0.9142	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C04:10	IRDREAVSM	0.9926	0.8019	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C04:07	IRDREAVSM	0.9925	0.8151	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:05	DREAVSMFL	0.9919	0.8863	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:27	IRDREAVSM	0.9912	0.9426	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:29	IRDREAVSM	0.9833	0.9139	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:05	IRDREAVSM	0.9826	0.8996	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:13	IRDREAVSM	0.978	0.9087	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:46	IRDREAVSM	0.9665	0.9012	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:80	IRDREAVSM	0.9565	0.9406	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:67	IRDREAVSM	0.9565	0.9406	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:19	IRDREAVSM	0.948	0.7799	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:10	IRDREAVSM	0.9356	0.9699	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:03	IRDREAVSM	0.8496	0.8753	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B40:03	RDREAVSMF	0.7638	0.5915	8	17
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B73:01	DREAVSMFL	0.6941	0.7525	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B14:03	DREAVSMFL	0.6068	0.8331	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C04:14	IRDREAVSM	0.5187	0.8934	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C12:16	IRDREAVSM	0.1711	0.9481	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B40:04	REAVSMFL	0.9989	0.7279	10	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:02	REAVSMFL	0.973	0.9634	10	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B27:06	IRDREAVSM	0.998	0.7741	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:31	DREAVSMFL	0.9963	0.8997	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:01	IRDREAVSM	0.9935	0.7218	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B27:09	IRDREAVSM	0.9929	0.714	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:05	DREAVSMFL	0.9927	0.9419	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C18:01	IRDREAVSM	0.9926	0.806	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C04:01	IRDREAVSM	0.9925	0.8151	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:31	IRDREAVSM	0.9894	0.9102	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:17	IRDREAVSM	0.988	0.9524	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B38:05	IRDREAVSM	0.9851	0.9656	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:02	IRDREAVSM	0.9565	0.9406	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:04	IRDREAVSM	0.9458	0.9413	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-A02:14	AVSMFLNTL	0.9098	0.5513	12	21
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C06:06	IRDREAVSM	0.8643	0.9864	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-A32:01	AVSMFLNTL	0.8515	0.9677	12	21
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:22	IRDREAVSM	0.8481	0.7763	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:09	DREAVSMFL	0.847	0.748	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:11	DREAVSMFL	0.8367	0.6686	9	18
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B39:11	IRDREAVSM	0.7739	0.7624	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C03:67	IRDREAVSM	0.7645	0.9772	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:09	IRDREAVSM	0.7122	0.8372	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C04:04	IRDREAVSM	0.6405	0.9087	7	16
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-B15:53	RDREAVSMF	0.452	0.9478	8	17
WNT2-ST7	chr7	116937666	chr7	116739816	1153	HLA-C07:22	IRDREAVSMF	0.994	0.7595	7	17

Top

Potential FusionNeoAntigen Information of WNT2-ST7 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of WNT2-ST7

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
847	CIRDREAVSMFLNT	WNT2	ST7	chr7	116937666	chr7	116739816	1153

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of WNT2-ST7

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	847	CIRDREAVSMFLNT	-7.15543	-7.26883
HLA-B14:02	3BVN	847	CIRDREAVSMFLNT	-4.77435	-5.80965
HLA-B52:01	3W39	847	CIRDREAVSMFLNT	-6.80875	-6.92215
HLA-B52:01	3W39	847	CIRDREAVSMFLNT	-4.20386	-5.23916
HLA-A11:01	4UQ2	847	CIRDREAVSMFLNT	-7.5194	-8.5547
HLA-A11:01	4UQ2	847	CIRDREAVSMFLNT	-6.9601	-7.0735
HLA-A24:02	5HGA	847	CIRDREAVSMFLNT	-7.52403	-7.63743
HLA-A24:02	5HGA	847	CIRDREAVSMFLNT	-5.82433	-6.85963
HLA-B27:05	6PYJ	847	CIRDREAVSMFLNT	-3.28285	-4.31815
HLA-B44:05	3DX8	847	CIRDREAVSMFLNT	-5.91172	-6.94702
HLA-B44:05	3DX8	847	CIRDREAVSMFLNT	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of WNT2-ST7

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
WNT2-ST7	chr7	116937666	chr7	116739816	10	18	REAVSMFL	GAGAGGCAGTGAGCATGTTTTTGA
WNT2-ST7	chr7	116937666	chr7	116739816	12	21	AVSMFLNTL	CAGTGAGCATGTTTTTGAACACATTAA
WNT2-ST7	chr7	116937666	chr7	116739816	7	16	IRDREAVSM	TCAGGGACCGAGAGGCAGTGAGCATGT
WNT2-ST7	chr7	116937666	chr7	116739816	7	17	IRDREAVSMF	TCAGGGACCGAGAGGCAGTGAGCATGTTTT
WNT2-ST7	chr7	116937666	chr7	116739816	8	17	RDREAVSMF	GGGACCGAGAGGCAGTGAGCATGTTTT
WNT2-ST7	chr7	116937666	chr7	116739816	8	18	RDREAVSMFL	GGGACCGAGAGGCAGTGAGCATGTTTTTGA
WNT2-ST7	chr7	116937666	chr7	116739816	9	18	DREAVSMFL	ACCGAGAGGCAGTGAGCATGTTTTTGA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of WNT2-ST7

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LGG	WNT2-ST7	chr7	116937666	ENST00000265441	chr7	116739816	ENST00000265437	TCGA-HT-A61C-01A

Top

Potential target of CAR-T therapy development for WNT2-ST7

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000265437

512_532

586.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000265437

62_82

586.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000393443

15_35

500.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000393443

512_532

500.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000393443

62_82

500.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000393451

512_532

555.0

Transmembrane

Helical

Tgene

ST7

chr7:116937666

chr7:116739816

ENST00000393451

62_82

555.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to WNT2-ST7

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to WNT2-ST7

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)